Overview

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ISIS 702843 Administered Subcutaneously to Healthy Volunteers

Status:
Completed
Trial end date:
2018-09-25
Target enrollment:
Participant gender:
Summary
The purpose is to assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IONIS TMPRSS6-Lrx Administered Subcutaneously for up to 44 Healthy Volunteers
Phase:
Phase 1
Details
Lead Sponsor:
Ionis Pharmaceuticals, Inc.